AbbVie

Recent News About AbbVie

BOTOX plans to empower 50,000 women entrepreneurs by 2030 through The Confidence Project

By Business Daily | May 1, 2025

Allergan Aesthetics, a division of AbbVie, has reaffirmed its commitment to supporting women entrepreneurs through its BOTOX Cosmetic initiative named "The Confidence Project: Empowering Women Entrepreneurs."

Allergan Aesthetics unveils new faculty for inaugural AMI training centers

By Business Daily | Apr 30, 2025

Allergan Aesthetics, a company under AbbVie, has announced the launch of the inaugural Allergan Medical Institute (AMI) Training Centers Faculty.

AbbVie seeks FDA approval for TrenibotE to treat glabellar lines

By Business Daily | Apr 24, 2025

AbbVie has taken a significant step in the aesthetics field by submitting a Biologics License Application to the U.S. Food and Drug Administration for its product trenibotulinumtoxinE (TrenibotE).

AbbVie to release first-quarter 2025 earnings on April 25

By Business Daily | Mar 31, 2025

AbbVie is set to release its first-quarter financial outcomes for 2025 on April 25, prior to the market opening.

AbbVie to present oncology advances at AACR Annual Meeting 2025

By Business Daily | Mar 26, 2025

AbbVie has announced that it will present new data from its early oncology research at the American Association of Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025.

Allergan showcases innovation at AMWC 2025 with new AA Signature program

By Business Daily | Mar 24, 2025

Allergan Aesthetics, a subsidiary of AbbVie, is showcasing its latest innovations at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from March 27 to March 29, 2025.

ELAHERE shows survival benefits in Phase 3 trial for resistant ovarian cancer

By Business Daily | Mar 15, 2025

AbbVie has released the final data from its Phase 3 MIRASOL trial, demonstrating a notable survival benefit for ELAHERE (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.

AbbVie set to present at Leerink Partners Global Healthcare Conference

By Business Daily | Mar 4, 2025

AbbVie has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.

AbbVie partners with Gubra for obesity treatment using amylin analog

By Business Daily | Mar 3, 2025

AbbVie and Gubra have announced a license agreement to develop an amylin analog, GUB014295, for obesity treatment.

AbbVie announces participation in TD Cowen's annual health care conference

By A. I. Benavidez | Feb 26, 2025

AbbVie is set to participate in the TD Cowen's 45th Annual Health Care Conference, scheduled for Wednesday, March 5, 2025.

AbbVie names CEO Robert A. Michael as new chairman

By A. A. Sanchez | Feb 14, 2025

AbbVie has announced that its board of directors unanimously elected CEO Robert A. Michael to also serve as chairman, effective July 1, 2025.

AbbVie announces quarterly cash dividend payable in May

By A. A. Sanchez | Feb 13, 2025

The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share.

AbbVie partners with Xilio Therapeutics on new cancer treatment development

By A. A. Sanchez | Feb 12, 2025

AbbVie and Xilio Therapeutics have entered into a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies.

Allergan announces new aesthetics training centers opening across the U.S

By A. A. Sanchez | Feb 12, 2025

Allergan Aesthetics, a company under AbbVie, is set to open three new Allergan Medical Institute (AMI) Training Centers in the United States.

FDA approves new antibiotic EMBLAVEO for resistant intra-abdominal infections

By K. R. Nelson | Feb 7, 2025

The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO, a combination of aztreonam and avibactam, for treating adults with complicated intra-abdominal infections (cIAI).

Trending

Recent News About AbbVie

Free Now Foundation marks anniversary with dinner featuring Del Bigtree & Steve Kirsch

Empower Pharmacy CEO on compounding pharmacy challenges: 'Big pharma lobbying is more than anybody else more than any industry by far'

Colorado bill could impose new rules on ridesharing, threaten industry’s future

Senior Policy Strategist of ACLU Colorado: HB25-1291 gives consumers 'less ability to consent to the collection of their data'

Oregon Legislative Assembly introduces new laws for transportation network companies